Pulmonary hypertension in heart failure with preserved ejection fraction: A plea for proper phenotyping and further research

European Heart Journal

Volumn 38, Issue 38, 2017, Pages 2869-2873

  Hoeper, Marius M ^a   Lam, Carolyn S P ^b   Vachiery, Jean Luc ^c   Bauersachs, Johann ^a   Gerges, Christian ^d   Lang, Irene M ^d   Bonderman, Diana ^d   Olsson, Karen M ^a   Gibbs, J Simon R ^e,f   Dorfmuller, Peter ^g   Guazzi, Marco ^h   Galie, Nazzareno ⁱ   Manes, Alessandra ⁱ   Handoko, M Louis ^j   Vonk Noordegraaf, Anton ^j   Lankeit, Mareike ^k   Konstantinides, Stavros ^l,m   Wachter, Rolf ⁿ   Opitz, Christian ^o   Rosenkranz, Stephan ^p  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ERASME HOSPITAL   (Belgium)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^m DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

ⁿ UNIVERSITY OF GÖTTINGEN   (Germany)

^o German Red Cross Hospital   (Germany)

^p UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; SACUBITRIL PLUS VALSARTAN; SODIUM NITRITE; SPIRONOLACTONE;

ARTERY COMPLIANCE; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG ARTERY PRESSURE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYMPTOMATOLOGY; COMPLICATION; GLOBAL HEALTH; HEART FAILURE; HEART STROKE VOLUME; MEDICAL RESEARCH; MORBIDITY; PHYSIOLOGY; PROCEDURES; SURVIVAL RATE;

BIOMEDICAL RESEARCH; GLOBAL HEALTH; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MORBIDITY; STROKE VOLUME; SURVIVAL RATE;

EID: 85032159863     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw597     Document Type: Article

References (41)

1. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol 2009;53:1119-1126.
2. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996-1004.
3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
4. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016;37:67-119.
5. Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, Maurer G, Lang IM. Diastolic pulmonary vascular pressure gradient: A predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 2013;143:758-766.
6. Gerges M, Gerges C, Lang IM. How to define pulmonary hypertension due to left heart disease. Eur Respir J 2016;48:553-555.
7. Vachiery JL, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013;62(25 Suppl):D100-D108.
8. Handoko ML, De Man FS, Oosterveer FP, Bogaard HJ, Vonk-Noordegraaf A, Westerhof N. A critical appraisal of transpulmonary and diastolic pressure gradients. Physiol Rep 2016;4:pii: E12910.
9. Ibe T, Wada H, Sakakura K, Ikeda N, Yamada Y, Sugawara Y, Mitsuhashi T, Ako J, Fujita H, Momomura S. Pulmonary hypertension due to left heart disease: The prognostic implications of diastolic pulmonary vascular pressure gradient. J Cardiol 2016;67:555-559.
10. Dragu R, Rispler S, Habib M, Sholy H, Hammerman H, Galie N, Aronson D. Pulmonary arterial capacitance in patients with heart failure and reactive pulmonary hypertension. Eur J Heart Fail 2015;17:74-80.
11. Tampakakis E, Leary PJ, Selby VN, De Marco T, Cappola TP, Felker GM, Russell SD, Kasper EK, Tedford RJ. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 2015;3:9-16.
12. Al-Naamani N, Preston IR, Paulus JK, Hill NS, Roberts KE. Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail 2015;3:467-474.
13. Brittain EL, Assad TR, Hemnes AR, Newman JH. The diastolic pressure gradient does not-and should not-predict outcomes. JACC Heart Fail 2015;3:845.
14. Borlaug BA. In search of new targets and endpoints in heart failure with preserved ejection fraction. JACC Heart Fail 2015;3:475-477.
15. Tedford RJ, Beaty CA, Mathai SC, Kolb TM, Damico R, Hassoun PM, Leary PJ, Kass DA, Shah AS. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant 2014;33:289-297.
16. Naeije R, Hemnes AR. The difficult diagnosis of pulmonary vascular disease in heart failure. Eur Respir J 2016;48:308-310.
17. Galiè N, Manes A, Palazzini M. The difficult diagnosis of pulmonary vascular disease in heart failure. Eur Respir J 2016;48:311-314.
18. Gerges M, Gerges C, Pistritto AM, Lang MB, Trip P, Jakowitsch J, Binder T, Lang IM. Pulmonary hypertension in heart failure. epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med 2015;192:1234-1246.
19. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011;4:257-265.
20. Opitz CF, Hoeper MM, Gibbs JSR, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D'Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Gruenig E, Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S. Pre-capillary, combined, and post-capillary pulmonary hypertension: A pathophysiological continuum?. J Am Coll Cardiol 2016;68:368-378.
21. Robbins IM, Hemnes AR, Pugh ME, Brittain EL, Zhao DX, Piana RN, Fong PP, Newman JH. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014;7:116-122.
22. D'Alto M, Romeo E, Argiento P, Motoji Y, Correra A, Di Marco GM, Mattera Iacono A, Barracano R, D'andrea A, Rea G, Sarubbi B, Russo MG, Naeije R. Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension. Chest 2016; pii: S0012-3692(16)57833-7.
23. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:588-595.
24. Andersen MJ, Olson TP, Melenovsky V, Kane GC, Borlaug BA. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail 2015;8:41-48.
25. Maor E, Grossman Y, Balmor RG, Segel M, Fefer P, Ben-Zekry S, Buber J, DiSegni E, Guetta V, Ben-Dov I, Segev A. Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail 2015;17:151-158.
26. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016;37:942-954.
27. Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricularpulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J 2016; pii: Ehw241.
28. Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:441-449.
29. Olson TP, Johnson BD, Borlaug BA. Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:490-498.
30. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014;35:3452-3462.
31. Mohammed SF, Hussain I, AbouEzzeddine OF, Takahama H, Kwon SH, Forfia P, Roger VL, Redfield MM. Right ventricular function in heart failure with preserved ejection fraction: A community-based study. Circulation 2014;130:2310-2320.
32. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation 2016;134:73-90.
33. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34-42.
34. Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 2015;66:1672-1682.
35. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-1395.
36. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial. Lancet 2016;387:453-461.
37. Melenovsky V, Andersen MJ, Andress K, Reddy YN, Borlaug BA. Lung congestion in chronic heart failure: Haemodynamic, clinical, and prognostic implications. Eur J Heart Fail 2015;17:1161-1171.
38. Andersen MJ, Hwang SJ, Kane GC, Melenovsky V, Olson TP, Fetterly K, Borlaug BA. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: Pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail 2015;8:542-550.
39. Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, Bojic A, Lam CS, Frey R, Ochan Kilama M, Unger S, Roessig L, Lang IM. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): A randomized, doubleblind, placebo-controlled, single-dose study. Chest 2014;146:1274-1285.
40. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: A randomized controlled trial. Eur Heart J 2015;36:2565-2573.
41. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164-174.